(Q42930906)

11 November 2017

title

Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer (English)

1 reference

11 November 2017

1 reference

Christos Chouaid

4

0 references

Alain Vergnenegre

series ordinal

5

object named as

Alain Vergnenègre

1 reference

11 November 2017

3

Helge G Bischoff

1 reference

11 November 2017

2

David F Heigener

1 reference

11 November 2017

Javier de Castro Carpeño

series ordinal

6

object named as

Javier de Castro Carpeño

1 reference

11 November 2017

8

Stefan Walzer

1 reference

11 November 2017

1

Mark Nuijten

1 reference

11 November 2017

7

Rick Aultman

1 reference

11 November 2017

Uwe Siebert

9

1 reference

11 November 2017

publication date

1 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

volume

69 Suppl 1

1 reference

11 November 2017

page(s)

S4-10

1 reference

EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Indirect comparisons of competing interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2810%2970132-X

7 January 2021

10.1016/S0169-5002(10)70132-X

Identifiers

DOI

1 reference

11 November 2017

1 reference